An updated guideline on pharmacotherapy of obesity management in adults includes six new and seven revised recommendations, ...

Patients with psoriasis have significantly more difficulty sleeping, particularly in new environments, than matched ...

Shares of Eli Lilly (NYSE: LLY), the pharmaceuticals giant and maker of the Mounjaro and Zepbound weight loss drugs, saw its ...

Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...

The up to $100 million in state tax incentives for a $3 billion Eli Lilly expansion in Kenosha County isn’t the only tax ...

This will be the first time the option has been taken up since it was introduced at the beginning of 2025, under the Medical ...

Eli Lilly and Company (NYSE: LLY) is one of the Good Stocks to Invest in Now. On August 7, Eli Lilly and Company (NYSE:LLY) ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

A transformative moment in the global fight against obesity has emerged with the announcement of positive topline results ...

Eli Lilly and Company (NYSE: LLY) is one of the top most profitable NYSE stocks to buy now. On August 7, Leerink downgraded ...

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...